Thank you for joining the weekly webinar!
We are admitting audience members from the waiting room.
Please allow a few moments for the webinar to begin.
HEALEY ALS Platform Trial:

Common Protocol and Shared Infrastructure

Regimen A
Regimen B
Regimen C
Regimen D
Regimen E
Regimen F
Regimen G

Screening Period
Randomized Period 24 weeks
Open-Label Extension Period (Active Treatment Extension)

ENROLLMENT COMPLETE
ENROLLING
ENROLLING
Exploratory Endpoints

Endpoint Development Engine

- DNA
- Neurofilaments
- Biomarkers (Blood, Urine, CSF)
- Speech / Digital
Enrollment Update: Regimen F and Regimen G

- 393 participants consented to Master Protocol since RGF and RGG initiated
- 329 participants assigned to RGF or RGG
- 286 participants randomized within RGF or RGG

Thank You for your partnership in ALS research (as of 10/19/23)
63 Sites Currently Active

(as of 10/19/23)
Checking Site Status Online

List of Participating Sites

Sites marked "Recruiting" are currently enrolling participants. Sites marked "Active, Not recruiting" are active in the Platform Trial (for example, they are following participants in ongoing regimens that have already completed enrollment) but are not enrolling new participants at this time.

<table>
<thead>
<tr>
<th>Site</th>
<th>State</th>
<th>Enrollment Status</th>
<th>Trial Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barrow Neurological Institute</td>
<td>AZ</td>
<td>Recruiting</td>
<td>Whitney Dailey</td>
</tr>
<tr>
<td>Cedars-Sinai Medical Center</td>
<td>CA</td>
<td>Recruiting</td>
<td>Sophia Mostowy</td>
</tr>
<tr>
<td>Forbes Norris MDA/ALS Research Center,</td>
<td>CA</td>
<td>Recruiting</td>
<td>Teji Dulai</td>
</tr>
<tr>
<td>California Pacific Medical Center</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaiser Permanente, Los Angeles Medical</td>
<td>CA</td>
<td>Recruiting</td>
<td>Mary H. Berganza</td>
</tr>
<tr>
<td>Medical Center</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
This public webpage provides:

1. General Brochure and Biomarkers Brochure
2. Overview of science behind Regimen F and Regimen G
3. Links to download relevant brochures, including the Lumbar Puncture Brochure
4. Links to view relevant videos and webinar recordings

Regimen F: ABBV-CLS-7262, by Calico and AbbVie - Now Recruiting
- Watch a webinar about the science behind ABBV-CLS-7262
- Watch this video for more information on the mechanism of action behind ABBV-CLS-7262.
- Download Regimen F Brochure
- Download Lumbar Puncture Brochure
- Step by Step Guide to Lumbar Punctures: Watch short video

Regimen G: DNL343, by Denali Therapeutics
- Download Regimen G Brochure
- Watch a webinar about the science behind DNL343

https://www.massgeneral.org/neurology/als/research/first-platform-trial-treatments
Patient Navigation
Central resource for people living with ALS

Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar registration: https://bit.ly/3r6Nd2L
ALS Link sign-up: https://bit.ly/3o2Ds3m

Upcoming Webinars:
October 26th- weekly Q&A
November 2nd- weekly Q&A
November 9th- weekly Q&A and EAP discussion with Dr. Suma Babu (Mass General)